Blue Shield of California’s zero-dollar biosimilar strategy: 7 notes

Becker's Healthcare October 2, 2024
Rylee Wilson

Blue Shield of California will purchase Fresenius Kabi’s Humira biosimilar directly from the manufacturer, a deal that will cut costs and improve patient adherence, the insurer said.

Blue Shield of California will pay $525 per monthly dose of the biosimilar, compared to the typical market reported net price of Humira of $2,100, according to an Oct. 1 news release from the insurer.

Here are five things to know about the deal:

1. Evio Pharmacy Solutions, a company backed by several Blue Cross Blue Shield plans, negotiated the deal.
2. Most Blue Shield commercial members will pay nothing out of pocket for Fresenius’ biosimilar. The move is expected to improve medication adherence, Blue Shield of California said.
...

Today's Sponsors

Today's Sponsor